Published in Oral Oncol on October 01, 2003
Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res (2010) 1.26
Salivary gland carcinomas. Oral Maxillofac Surg (2012) 1.20
Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. Head Neck Oncol (2010) 1.05
Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer (2012) 1.02
Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival. Neoplasia (2006) 0.98
Trastuzumab for the treatment of salivary duct carcinoma. Oncologist (2013) 0.94
HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer (2004) 0.94
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck (2009) 0.92
HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily. Oncol Lett (2013) 0.91
Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer (2010) 0.91
Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head Neck (2013) 0.87
Concern Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol (2012) 0.86
Clinical features of brain metastasis from salivary gland tumors. J Clin Neurosci (2013) 0.86
Copy number increase of ACTN4 is a prognostic indicator in salivary gland carcinoma. Cancer Med (2014) 0.85
Salivary mucoepidermoid carcinoma revisited. Eur Arch Otorhinolaryngol (2014) 0.85
Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma. Case Rep Oncol (2013) 0.83
Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Salivary Gland Carcinomas: A Review of Literature. J Clin Diagn Res (2015) 0.83
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol (2011) 0.83
Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget (2015) 0.83
Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature. Avicenna J Med (2012) 0.83
Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch (2012) 0.82
High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. J Transl Med (2014) 0.82
Signaling pathways in adenoid cystic cancers: implications for treatment. Cancer Biol Ther (2009) 0.81
Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncol (2005) 0.81
Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance. Am J Pathol (2013) 0.80
Postoperative radiotherapy in salivary ductal carcinoma: a single institution experience. Radiat Oncol J (2014) 0.80
Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res (2014) 0.79
Outcomes and prognostic factors in modern era management of major salivary gland cancer. Oral Oncol (2015) 0.79
Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literature. J Med Case Rep (2011) 0.77
Genomic landscape of salivary gland tumors. Oncotarget (2015) 0.76
Correlations of Human Epithelial Growth Factor Receptor 2 Overexpression with MUC2, MUC5AC, MUC6, p53, and Clinicopathological Characteristics in Gastric Cancer Patients with Curative Resection. Gastroenterol Res Pract (2015) 0.75
Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification. Case Rep Oncol (2016) 0.75
Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma. Case Rep Oncol Med (2014) 0.75
Unusual mucoepidermoid carcinoma of the liver misdiagnosed as squamous cell carcinoma by intraoperative histological examination. Diagn Pathol (2014) 0.75
New agents in the treatment for malignancies of the salivary and thyroid glands. Hematol Oncol Clin North Am (2008) 0.75
Phosphorylated epidermal growth factor receptor expression and KRAS mutation status in salivary gland carcinomas. Clin Oral Investig (2015) 0.75
Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands. Virchows Arch (2015) 0.75
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med (2003) 13.99
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol (2003) 11.94
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol (2009) 3.99
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood (2009) 3.84
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol (2013) 3.50
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol (2007) 3.29
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol (2012) 3.18
Case records of the Massachusetts General Hospital. Case 15-2006. A 46-year-old woman with sudden onset of abdominal distention. N Engl J Med (2006) 2.92
Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol (2006) 2.53
Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol (2007) 2.36
Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res (2002) 2.20
Human papillomavirus-associated adenocarcinoma of the base of the tongue. Hum Pathol (2013) 2.08
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol (2011) 2.03
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest (2012) 1.92
Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene (2004) 1.82
Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res (2012) 1.76
Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg (2003) 1.76
Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol (2009) 1.73
A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol (2011) 1.64
Head and neck cancers. J Natl Compr Canc Netw (2011) 1.64
PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol (2010) 1.57
Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck (2004) 1.55
A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila) (2008) 1.53
CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis. Leuk Lymphoma (2012) 1.52
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res (2008) 1.52
IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys (2008) 1.51
Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene (2002) 1.49
Can changing the terminology for benign aspirates reduce the atypia of undetermined significance/follicular lesion of undetermined significance rate in thyroid fine-needle aspirates? Cancer Cytopathol (2012) 1.45
Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol (2004) 1.45
Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2014) 1.39
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol (2005) 1.39
Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.35
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol (2005) 1.33
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res (2003) 1.32
Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist (2008) 1.30
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated fna be the preferred initial approach? Am J Clin Pathol (2011) 1.28
HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res (2004) 1.25
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res (2005) 1.23
Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base. AIDS (2003) 1.22
HPV-associated neuroendocrine carcinoma of the oropharynx: a rare new entity with potentially aggressive clinical behavior. Am J Surg Pathol (2012) 1.22
Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol (2006) 1.19
Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2012) 1.18
Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs (2004) 1.17
Biased view of the role of site-specific therapy in carcinoma of unknown primary. J Clin Oncol (2013) 1.16
A subset of cutaneous and soft tissue mixed tumors are genetically linked to their salivary gland counterpart. Genes Chromosomes Cancer (2011) 1.14
FNAB of benign thyroid nodules with papillary hyperplasia: a cytological and histological evaluation. Cancer Cytopathol (2014) 1.12
Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx. Am J Clin Pathol (2010) 1.11
Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer (2006) 1.08
A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer. PLoS One (2013) 1.08
Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer. Cancer (2011) 1.05
Cytomorphologic features of poorly differentiated thyroid carcinoma: a multi-institutional analysis of 40 cases. Cancer (2009) 1.05
Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol (2005) 1.05
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs (2007) 1.04
Neurolymphomatosis. J Neurooncol (2004) 1.02
Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol (2005) 1.01
PLAG1 alteration in carcinoma ex pleomorphic adenoma: immunohistochemical and fluorescence in situ hybridization studies of 22 cases. Head Neck Pathol (2012) 1.01
Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody. Mol Cancer Ther (2011) 1.00
Intensity-modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx. Head Neck (2011) 1.00
The atypical thyroid fine-needle aspiration: past, present, and future. Cancer Cytopathol (2011) 0.99
Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (2009) 0.98
HPV16 transmission between a couple with HPV-related head and neck cancer. Oral Oncol (2007) 0.98
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev (2014) 0.97
Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120. AIDS Res Hum Retroviruses (2003) 0.96
Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol (2012) 0.95
Trastuzumab for the treatment of salivary duct carcinoma. Oncologist (2013) 0.94
Native HIV type 1 virion surface structures: relationships between antibody binding and neutralization or lessons from the viral capture assay. AIDS Res Hum Retroviruses (2004) 0.94
Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. Head Neck (2014) 0.93
Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance. Am J Clin Pathol (2011) 0.93
Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer (2012) 0.92
The role of inflammation in head and neck cancer. Adv Exp Med Biol (2014) 0.92
Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg (2006) 0.91
Atypical glandular cells of undetermined significance (AGUS): Interobserver reproducibility in cervical smears and corresponding thin-layer preparations. Am J Clin Pathol (2002) 0.91
Real-time quantitative reverse transcription-PCR for cyclin D1 mRNA in blood, marrow, and tissue specimens for diagnosis of mantle cell lymphoma. Clin Chem (2003) 0.91
Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer (2012) 0.91
Prospective evaluation of acute graft-versus-host disease. Dig Dis Sci (2011) 0.90
A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck (2002) 0.90
Head and neck squamous cell carcinoma: new translational therapies. Mt Sinai J Med (2010) 0.90
Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2008) 0.90
Mucosal melanoma of the head and neck. J Natl Compr Canc Netw (2012) 0.89
Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. Int J Radiat Oncol Biol Phys (2012) 0.89
Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol (2013) 0.89
A patient-centered approach to counseling patients with head and neck cancer undergoing human papillomavirus testing: a clinician's guide. Oncologist (2013) 0.89
Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda System for reporting thyroid cytopathology. Cancer Cytopathol (2012) 0.89
Squamous cell carcinoma of the oral tongue in two patients previously exposed to long-term pegylated liposomal doxorubicin. Oncologist (2012) 0.88
Case records of the Massachusetts General Hospital. Case 26-2007 - a 61-year-old man with recurrent fevers. N Engl J Med (2007) 0.88
The frequency of 'atypia of undetermined significance' interpretations for thyroid fine-needle aspirations is negatively correlated with histologically proven malignant outcomes. Acta Cytol (2011) 0.88